Brain & neurodegeneration
Alzheimer's, Parkinson's and brain aging. The first antibodies that slow early Alzheimer's are approved and carry real risks; most other approaches are still in trials or earlier.
5 approaches: 1 available now, 3 in human trials, 1 experimental. Grades from A to D describe the human evidence; how we rate.
| Approach | Stage | Evidence | One-line verdict | Reviewed |
|---|---|---|---|---|
| Anti-amyloid antibodies (Lecanemab / Donanemab)Brain & neurodegeneration | Approved | Aoutcome RCTs | Slows cognitive decline by about 27 to 35% in early Alzheimer's, which is not a cure, and brain swelling or bleeding is a real risk. | Jul 2026 |
| 40 Hz gamma sensory stimulation (GENUS / Cognito) — Alzheimer'sBrain & neurodegeneration | Phase 3, no results yet | Csmall human trial | Strong mouse data and one small human feasibility trial, but the Phase 3 has not reported and human efficacy is not established. | Sep 2026 |
| GLP-1 analogs (repurposed) for brain healthBrain & neurodegeneration | Phase 2/3 | Cemerging data | Early signals of better memory, but large trials are still running and no brain benefit is proven. | Jul 2026 |
| Stem-cell dopamine neurons for Parkinson's (Aspen ASPIRO / Sumitomo raguneprocel)Brain & neurodegeneration | Phase 1/2, conditional approval in Japan | Csmall cohorts | Motor symptoms eased or stabilised for up to two years in small cohorts, with no large randomised results yet. | Jul 2026 |
| Psilocybin for brain aging & neurodegenerationBrain & neurodegeneration | Speculative | Done case report | A single Alzheimer's case report and preliminary lab data, not a basis for treating brain aging. | Jul 2026 |
Other topics
Aging itself Cancer Heart & cardiovascular Diabetes & metabolic All 46 entries